RESUMO
RESUMEN Introducción: La muerte súbita es la principal causa de muerte en pacientes con ERC en hemodiálisis crónica (HD). Objetivo: Evaluar la prevalencia de hiperkalemia (HK) en los pacientes tratados con HD, los factores de riesgo asociados al desarrollo de la misma, y determinar su asociación con mortalidad de cualquier causa y mortalidad cardiovascular. Materiales y métodos: Estudio de cohorte retrospectiva. Se incluyeron 153 pacientes en HD. Se registró el K (potasio) sérico desde noviembre de 2020 durante 6 meses en periodo interdialítico corto. Resultados: La prevalencia de HK (K>5.1) fue de 35.3 % (n=54). Al comparar a los hiperkalemicos (HK) vs normokalemicos (NK) encontramos diferencias significativas en edad (61 vs 68 años p: 0.013), tiempo en diálisis (83 vs 51 meses p= 0.002), acceso vascular (FAV/prótesis) (88.9 vs 67.7% p= 0.016) y uso de quelantes del K (20.4 vs 4 % p= 0.003), con una tendencia a la significancia en el score de Charlson (5 vs 6 p= 0.07). En el análisis multivariado el Score de Charlson (OR: 1.36, CICI 1.19-1.55, p< 0.001) y las hospitalizaciones (OR: 5, CI 2.18-11.68, p<0.001), se asociaron a mayor mortalidad, mientras que la HK se mantuvo como un factor protector (OR: 0.287, CI 0.124-0.664 p: 0.004). Conclusión: La HK se asoció con menor edad y score de Charlson respecto a los NK. La HK resultó se asoció en forma significativa con menor mortalidad de cualquier causa.
ABSTRACT Introduction: Sudden death is the leading cause of death in patients with CKD on chronic hemodialysis (HD). Objective: To evaluate the prevalence of hyperkalemia (HK) in patients treated with HD, the risk factors associated with its development, and to determine its association with all-cause mortality and cardiovascular mortality. Materials and methods: Retrospective cohort study including 153 HD patients. Serum K (potassium) was recorded from November 2020 for six months in a short interdialytic period. Results: The prevalence of HK (K>5.1) was 35.3% (n=54). When comparing hyperkalemic (HK) vs. normokalemic (NK) patients, we found significant age differences (61 vs. 68 years p: 0.013), time on dialysis (83 vs. 51 months p= 0.002), vascular access (AVF/prosthesis) ( 88.9 vs. 67.7% p= 0.016) and use of K chelators (20.4 vs. 4% p= 0.003), with a tendency to significance in the Charlson score (5 vs. 6 p= 0.07). In the multivariate analysis, the Charlson Score (OR: 1.36, CICI 1.19-1.55, p<0.001) and hospitalizations (OR: 5, CI 2.18-11.68, p<0.001) were associated with higher mortality, while HK remained as a protective factor (OR: 0.287, CI 0.124%E2%80%930.664 p: 0.004). Conclusion: HK was associated with lower age and Charlson scores than NK. HK was significantly associated with lower all-cause mortality.
RESUMO
IntroductionThe humoral response to vaccines is the most used tool to evaluate the protection against SARS-CoV-2 infection. Dialysis patients are a high-risk population and have a reduced immune response to vaccination. ObjectiveTo assess the humoral response to homologous Gam-COVID-Vac (Sputnik V) and heterologous Sputnik V/mRNA-1273 (Moderna) vaccination in dialysis patients. MethodsSARS-CoV-2 anti-spike IgG (RBD) concentration was estimated 3-16 weeks after complete vaccination. Reactogenicity was evaluated until day 7 by patients s self-reported side events. Results107 participants were enrolled [n=84 homologous (SpV/SpV), n=23 heterologous (SpV/Mod)]. Median (IQR) age was 64 (50-75) years old and 79 (73.8%) were male. Additionally, 19 (22.6%) of the SpV/SpV and 4 (17.4%) of the SpV/Mod group had a prior confirmed SARS-CoV-2 infection (p=0.589). In the overall population, 103 patients reached seroconversion (96.3%). Anti-S-RBD IgG median titers (IQR) were higher in the heterologous [1222 (288-5680) BAU/mL] than in the homologous scheme [447 (100-1551) BAU/mL], p=0.022. In a linear model adjusted for age and gender, previous SARS-COV-2 infection (B: 1944.3; CI95: 1136.2-2753.4; p<0.001), and SpV/Mod vaccination scheme (B: 1241.5; CI95: 420.39-2062.6; p=0.003) were independently associated with anti-S-RBD levels. Finally, a higher frequency of adverse effects was associated with the heterologous scheme, although they were well tolerated by all individuals. ConclusionThe present study provides evidence that the homologous SpV/SpV and heterologous SpV/Mod schemes showed good efficacy and safety under dialysis conditions. These results could be useful for future vaccination strategies, especially aimed at this risk group.